Regulations.gov document
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics…
Other · FDA-2022-D-0235 · posted Jun 27, 2022
Key facts
| Document ID | FDA-2022-D-0235-0002 |
|---|---|
| Title | Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics Guidance for Industry DRAFT GUIDANCE |
| Document type | Other |
| Subtype | Guidance |
| Agency | FDA |
| Docket | FDA-2022-D-0235 |
| Posted | Jun 27, 2022 |
| Comment period opens | Jun 27, 2022 |
| Comments due | Sep 27, 2022 |
At a glance
- No Open for comment
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: